Cargando…
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models
BACKGROUND: Castrate resistant prostate cancer (CRPC) is often driven by constitutively active forms of the androgen receptor such as the V7 splice variant (AR-V7) and commonly becomes resistant to established hormonal therapy strategies such as enzalutamide as a result. The lysine demethylase LSD1...
Autores principales: | Regufe da Mota, Sergio, Bailey, Sarah, Strivens, Rosemary A., Hayden, Annette L., Douglas, Leon R., Duriez, Patrick J., Borrello, M. Teresa, Benelkebir, Hanae, Ganesan, A., Packham, Graham, Crabb, Simon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941811/ https://www.ncbi.nlm.nih.gov/pubmed/29760584 http://dx.doi.org/10.1186/s12935-018-0568-1 |
Ejemplares similares
-
Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021) -
4,5-Dimethoxycanthin-6-one is a novel LSD1 inhibitor that inhibits proliferation of glioblastoma cells and induces apoptosis and pyroptosis
por: Li, Wei, et al.
Publicado: (2022) -
Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival
por: Yang, Qing, et al.
Publicado: (2005) -
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
por: Sharp, Adam, et al.
Publicado: (2018) -
Histone methyltransferase SUV39H2 regulates LSD1-dependent CDH1 expression and promotes epithelial mesenchymal transition of osteosarcoma
por: Miao, Yingying, et al.
Publicado: (2021)